三只新股同日暗盘！最高大涨超275%，一手赚超1.1万港元

Core Viewpoint - The performance of three newly listed stocks in the Hong Kong market on December 22 showed significant divergence, closely related to their respective industry trends, with notable gains for AI-focused companies and a lackluster performance for an innovative drug company [2][3]. Group 1: Stock Performance - Nobikang, focused on AI industrial applications, saw a dramatic increase of 275.75%, closing at HKD 300.60 per share, with a total transaction volume of HKD 65.22 million [3]. - Qingsong Health, operating in the "AI + health" sector, rose by 127.95% to HKD 51.70 per share, benefiting from a large user base of 168 million registered users and over 1000 times subscription during the public offering [4]. - Hansai Aitai-B, in the innovative drug sector, only increased by 2.06%, closing at HKD 32.66 per share, despite a subscription rate of approximately 2600 times during the public offering [4]. Group 2: Market Outlook - The Hong Kong IPO market is expected to recover significantly in 2025, with around 100 companies projected to raise over HKD 250 billion, and predictions for 2026 suggest 150-200 new listings with fundraising potentially exceeding HKD 300 billion [5]. - The success rate and apparent return of new stocks have improved, with nearly 70% of new stocks achieving gains on their first day, and 16 stocks showing cumulative increases of over 100% throughout the year [5][6]. - The importance of selecting quality stocks is emphasized, as recent data indicates that the majority of returns from IPOs are generated by a small number of high-performing stocks [6].